Shastri S, Mroszczak E, Prichard R K, Parekh P, Nguyen T H, Hennessey D R, Schiltz R
Am J Vet Res. 1980 Dec;41(12):2095-2101.
Three mean particle sizes of oxfendazole raw material (1.65 micron, lot A; 3.2 micron, 10t B; 12.0 micron, lot C) were prepared and identically formulated as corresponding (A, B, and C) suspensions at 2.26% (W/V) concentration. Studies involving microscopic examination, scanning electron microscope analysis, particle size distribution, and surface area measurement were carried out on raw materials. In vitro dissolution profiles were obtained for the suspensions. A comparative bioavailability study of these 3 suspensions was performed in 12 sheep with each sheep given each formulation in a Latin square crossover study design; oxfendazole was dosed at rate of 5 mg/kg of body weight. Plasma-value measurements were made followed by an analysis of various bioavailability studies. Plasma area values indicated that suspension C (dw = 12.0 micron) was significantly (P less than 0.05) less bioavailable than was suspension A (dw = 1.65 micron); there was no difference between suspension A and suspension B. Significant differences were not seen in biological half-life and maximum plasma concentrations. The term dw refers to that particle diameter (determined by Coulter counting) at which 50% of the oxfendazole mass was in the form of particles having a lesser diameter and 50% was in the form of particles having a greater diameter. In a separate study involving 20 Merino weaner sheep infected with benzimidazole-resistant Haemonchus contortus larvae, oxfendazole's anthelmintic efficacy was demonstrated in the 2.26% suspension dosage form (90% particles less than 10 micron) at a dosing rate of 5 mg/kg. A correlation was found between its anthelmintic activity and plasma area values when compared in individual sheep. Data demonstrated that substantial differences in particle size distribution of oxfendazole could influence its dissolution rate, plasma concentrations, and absorption characteristics, thus indicating that oxfendazole's absorption could be dissolution-rate limited.
制备了三种平均粒径的奥芬达唑原料药(1.65微米,A批次;3.2微米,10吨B批次;12.0微米,C批次),并将其以2.26%(W/V)的浓度配制成相应的(A、B和C)混悬液。对原料药进行了显微镜检查、扫描电子显微镜分析、粒径分布和表面积测量等研究。获得了混悬液的体外溶出曲线。在12只绵羊中进行了这3种混悬液的比较生物利用度研究,每只绵羊在拉丁方交叉研究设计中给予每种制剂;奥芬达唑的给药剂量为5毫克/千克体重。进行血浆值测量,随后对各种生物利用度研究进行分析。血浆面积值表明,混悬液C(dw = 12.0微米)的生物利用度显著低于混悬液A(dw = 1.65微米)(P小于0.05);混悬液A和混悬液B之间没有差异。在生物半衰期和最大血浆浓度方面未观察到显著差异。术语dw是指奥芬达唑质量的50%以直径较小的颗粒形式存在,50%以直径较大的颗粒形式存在时的粒径(通过库尔特计数法测定)。在另一项涉及20只感染了对苯并咪唑耐药的捻转血矛线虫幼虫的美利奴断奶绵羊的研究中,以5毫克/千克的给药剂量,在2.26%混悬液剂型(90%颗粒小于10微米)中证明了奥芬达唑的驱虫效果。在个体绵羊中比较时,发现其驱虫活性与血浆面积值之间存在相关性。数据表明,奥芬达唑粒径分布的显著差异会影响其溶出速率、血浆浓度和吸收特性,从而表明奥芬达唑的吸收可能受溶出速率限制。